HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Obicetrapib may prevent both heart disease and Alzheimer's

Louis Nervegna · Jul 07, 2026 · ♥ 19 reactions · 5 comments · original Facebook post
PCSK9, ezetimibe & newer drugsBrain health & dementiaLDL, ApoB & lipid panel
AI summary & key facts

Louis notes obicetrapib, a CETP inhibitor, may treat both CVD and Alzheimer's. A Phase 2 prevention trial will include 75% APOE4 carriers. BROADWAY showed slower p-tau217 rise over 12 months.

This new cholesterol drug obicetrapib may simultaneously prevent/treat both heart disease and Alzheimer’s.

I’ve talked about it before.

It belongs to a class of drugs called CETP inhibitors, which have previously failed as treatments for CVD: ↪ HDL and ApoA-I raising therapies repeatedly failed, so HDL is probably not directly causal.

This new drug appears to solve some of the problems of previous CETP inhibitor drugs in CVD, and looks especially promising for Alzheimer’s prevention.

See these previous posts:

  1. facebook.com/share/r/1Esd2shQ1b
  1. ↪ Obicetrapib lowers LDL and raises HDL on top of statins, but outcome benefit is unproven
  1. ↪ CETP inhibitor obicetrapib slowed p-tau217 accumulation in the BROADWAY analysis
  1. facebook.com/share/r/1C71h22JBY

#obicetrapibHD #cetpinhibitorHD #alzheimersHD #apoe4HD #ptau217HD #broadwayHD #spinozaHD

Research cited

Shared from apoe4.info · original post
yassinelab.orgObicetrapib and the Biology of Alzheimer’s PreventionBROADWAY showed a promising p-tau217 signal. The next test is whether a lipid drug can help the right biological population.yassinelab.org

A drug with a challenging name--obicetrapib (pronounced oh-bi-SEH-tra-pib)-- will soon be in a Phase 2 Alzheimer's prevention trial with 75% APOE 4 carriers.

🧠 Big Picture: Dr. Hussein Yassine, Director of the USC Center for Personalized Brain Health and the Yassine Lab, who focuses on APOE 4 and lipid biology, posted on 6/28 about why a drug in development for heart disease and/or high cholesterol may be beneficial for APOE 4/4 carriers with those risk factors--and a positive amyloid biomarker.

An excerpt from his 6/28 Substack at the link is below, with light editing and gratitude for Dr. Yassine's ability to explain complex ideas.

🔹 A recent analysis from the BROADWAY trial reported that obicetrapib slowed the rise of plasma p-tau217 over 12 months in people with cardiovascular disease. That finding deserves attention, especially because the effect was strongest in the small sub-group of APOE 4/4 carriers.

❤️ The question now is whether the signal reflects a real effect on Alzheimer’s biology, whether it is strongest in the right biological subgroup, and whether it eventually translates into cognition or function.

P-tau217 is one of the strongest blood biomarkers we have for Alzheimer’s disease biology. It often rises when amyloid and tau pathology are building in the brain. So when a drug changes p-tau217 in a randomized placebo-controlled study, the field should pay attention.

BROADWAY was designed as a cardiovascular lipid trial. The Alzheimer’s biomarker analysis was pre-specified before the trial started but it was still an analysis within a cohort recruited for another primary disease question. That distinction matters.

👉 The result can lead to an important hypothesis. It does not, by itself, prove Alzheimer’s prevention, clinical benefit, or disease modification.

🔹 Background: How Obicetrapib Affects Lipid Biology

Obicetrapib blocks cholesterol ester transfer protein (CETP), a protein that helps transfer cholesterol between lipoprotein particles in the blood.

When CETP is inhibited, LDL cholesterol falls. ApoB and non-HDL cholesterol fall. Lp(a) can fall. HDL cholesterol rises, and HDL particles may become larger or more functional.

BROADWAY enrolled people with cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia whose LDL cholesterol remained inadequately controlled despite lipid-lowering therapy.

In that population, obicetrapib lowered LDL-C, raised HDL-C, and lowered Lp(a).

🔹 The Alzheimer’s question is different: whether this peripheral lipid remodeling can also influence Alzheimer’s-related biology [through one or more] plausible pathways:

➤ The effect could be vascular, through lower LDL-C, ApoB, Lp(a), and improved vascular risk biology.
➤ It could be HDL-mediated, through larger or more functional HDL particles that support cholesterol efflux, antioxidant activity, and anti-inflammatory signaling.
➤ It could also involve amyloid handling, including a possible peripheral sink effect where remodeled HDL particles bind or help transport amyloid-related material in blood.

🔹Context is important: The Alzheimer’s biomarker substudy of p-tau levels was from a lipid-risk population, which may be exactly where a lipid-modifying drug is most likely to show a signal.

➤ Of the 1,535 participants in the biomarker analysis, 1,045 were APOE3/E3, 338 were APOE3/E4, 20 were APOE2/E4, and only 29 were APOE4/E4 .

👉 The most striking APOE4/E4 finding came from a small subgroup. Small subgroups can reveal real biology... but it requires replication before it can carry the weight of any clinical claim.

In the BROADWAY p-tau217 substudy, approximately 87% of APOE4 carriers had ASCVD, about 81% had hypertension, and about 38% had diabetes. Among APOE 4/4 participants specifically, about 86% had ASCVD, about 83% had hypertension, and about 45% had diabetes APOE 4/4 participants had higher p-tau217 at baseline, and participants with higher baseline p-tau217 appeared to show greater treatment effects.

🔹The Key Prevention Questions:

  1. Was the stronger APOE4/E4 reduction in p-tau 218l due to APOE4 biology, higher baseline p-tau217, lipid risk, ASCVD, or some combination of all these factors?
  2. Does that reduction lead to clinical benefit?

❤️SPINOZA: A trial recruiting 100 APOE 4/4 carriers and 125-150 APOE 3/4 carriers.

SPINOZA is a phase 2b randomized, double-blind, placebo-controlled trial testing obicetrapib in people with preclinical Alzheimer’s disease. Unlike BROADWAY, it is designed around Alzheimer’s prevention.

The primary endpoint is change in plasma p-tau217 at week 52. Secondary endpoints include Aβ42/40, p-tau217/Aβ42, p-tau217/Aβ42/40, p-tau181, and brain-derived tau. Cognition is exploratory and measured with the Preclinical Alzheimer Cognitive Composite 5, or PACC5.

SPINOZA plans to enroll up to 400 participants, including at least 100 APOE4/E4 participants, plus 125–150 APOE3/E4 and 125–150 APOE3/E3 participants [5].

🔹 SPINOZA will test the observed signal from the BROADWAY trial of lower p-tau217 in a preclinical Alzheimer’s population and will recruit a much larger 25% APOE4/E4 subgroup of the total participants..

⭐ KEY TAKE-AWAYS:

➤ For obicetrapib, the most informative population may be people with both Alzheimer’s biology and lipid biology: APOE4 plus elevated p-tau217, high LDL-C or ApoB, elevated Lp(a), low HDL function, ASCVD, metabolic syndrome, or combinations of these factors.
➤ Alzheimer’s prevention trials need to match the drug to the biology it is designed to modify. For obicetrapib, that biology is lipid metabolism.
➤ The right conclusion is not: Obicetrapib prevents Alzheimer’s disease.”
➤ The right conclusion is: “Obicetrapib produced a promising lipid-biology signal that now needs rigorous prospective testing in the right biological population.”
➤ That is how reproducible prevention science can move forward.

Dr. Yassine disclosed on his Substack that he sits on the advisory board of New Amsterdam Pharma, which is developing Obicetrapib.

No photo description available.
← newer: Eric Verdin's GLP-1 experiment improved glucose but caused rolder: Insulin resistance may be an adaptive response to nutrient e →